Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
Cancer Research UK
Cancer Research UK
Cancer Research UK
University of Pittsburgh
Marengo Therapeutics, Inc.
Revolution Medicines, Inc.
Stanford University
Hoffmann-La Roche
Revolution Medicines, Inc.
Revolution Medicines, Inc.
VA Office of Research and Development
BBB-Therapeutics B.V.